Genta Will Develop Daiichi’s Tesetaxel
This article was originally published in The Pink Sheet Daily
Executive Summary
After the oral taxane was put on clinical hold, Genta says it has clear guidance from FDA on how to proceed with development.
You may also be interested in...
Genta Poised To Restart Tesetaxel Studies
FDA lifts clinical hold on Phase II oral taxane now headed back to the clinic in the second half.
Genta Poised To Restart Tesetaxel Studies
FDA lifts clinical hold on Phase II oral taxane now headed back to the clinic in the second half.
Genta Expects Genasense Appeal Decision This Quarter After FDA Extends Review
Company previously had expected to hear from FDA in Q4 2007 following formal appeal of “not approvable” letter for CLL.